Rebamipide

Rebamipide

Rebamipide

Amino acid derivative

Rebamipide, an amino acid derivative of 2-(1H)-quinolinone, is used for mucosal protection,[1] healing of gastroduodenal ulcers, and treatment of gastritis.[2] It works by enhancing mucosal defense, scavenging free radicals,[3] and temporarily activating genes encoding cyclooxygenase-2.[4]

Quick Facts Clinical data, Trade names ...

Studies have shown that rebamipide can fight the damaging effects of NSAIDs on the GIT mucosa,[5] and more recently, the small intestine, but not for naproxen-induced gastric damage.[6]

Availability

Rebamipide is used in a number of Asian countries including Japan (marketed as Mucosta), South Korea, China[7] and India (where it is marketed under the trade name Rebagen). It is also approved in Russia under the brand name Rebagit.[8]

References

  1. [1]
    Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A (September 1998). "Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing". Digestive Diseases and Sciences. 43 (9 Suppl): 5S–13S. PMID 9753220.
  2. [2]
    Arakawa T, Watanabe T, Fukuda T, Yamasaki K, Kobayashi K (November 1995). "Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine". Digestive Diseases and Sciences. 40 (11): 2469–72. doi:10.1007/bf02063257. PMID 7587834. S2CID 22807270.
  3. [3]
    Takumida M, Anniko M (January 2009). "Radical scavengers for elderly patients with age-related hearing loss". Acta Oto-Laryngologica. 129 (1): 36–44. doi:10.1080/00016480802008215. PMID 18607930. S2CID 16906464.
  4. [4]
    Tarnawski AS, Chai J, Pai R, Chiou SK (February 2004). "Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?". Digestive Diseases and Sciences. 49 (2): 202–9. doi:10.1023/b:ddas.0000017439.60943.5c. PMID 15104358. S2CID 31756608.
  5. [5]
    Zhang S, Qing Q, Bai Y, Mao H, Zhu W, Chen Q, Zhang Y, Chen Y (July 2013). "Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis". Digestive Diseases and Sciences. 58 (7): 1991–2000. doi:10.1007/s10620-013-2606-0. PMID 23456504. S2CID 4887031.
  6. [6]
    Gagliano-Jucá T, Moreno RA, Zaminelli T, Napolitano M, Magalhães AF, Carvalhaes A, Trevisan MS, Wallace JL, De Nucci G (June 2016). "Rebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial". BMC Gastroenterology. 16 (1): 58. doi:10.1186/s12876-016-0472-x. PMC 4893238. PMID 27259970.
  7. [7]
    "Rebamipide". Drugs.com.
  8. [8]
    "Registration Sertificate: Rebagit (rebamipide) Film-Coated Tablets" (in Russian). Russian State Register of Medicines. Retrieved 10 June 2017.
Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Rebamipide, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.